National Pension Service Trims Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

National Pension Service reduced its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,084,889 shares of the company’s stock after selling 85,751 shares during the period. National Pension Service owned approximately 0.27% of Teva Pharmaceutical Industries worth $67,991,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Smithfield Trust Co grew its position in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after purchasing an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $50,000. Venturi Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $60,000. Ameliora Wealth Management Ltd. purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $66,000. Finally, Farther Finance Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 273.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock valued at $82,000 after purchasing an additional 3,323 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on TEVA. Barclays reduced their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Finally, StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $23.57.

Insider Buying and Selling

In related news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Trading Down 2.7 %

NYSE:TEVA opened at $16.32 on Friday. The company’s 50 day moving average price is $19.75 and its 200-day moving average price is $18.48. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock has a market cap of $18.49 billion, a price-to-earnings ratio of -11.26, a PEG ratio of 1.44 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.